Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Lung cancer is the leading cause of cancer mortality. As a heterogeneous disease, it has
different subtypes and various treatment modalities. In addition to conventional surgery …

Hepatocyte growth factor receptor (MET) tyrosine kinase inhibitors (MET TKIs) have been
found to have efficacy against advanced NSCLC with mutations causing MET exon 14 …

The majority of NTRK1, NTRK2, and NTRK3 rearrangements result in increased expression
of the kinase portion of the involved gene due to its fusion to an actively transcribed gene …

RET-kinase-activating gene rearrangements occur in approximately 1–2% of non-small-cell
lung carcinomas (NSCLCs). Their reliable detection requires next-generation sequencing …

Background Dysregulation of the mesenchymal epithelial transition (MET) pathway
contributes to poor clinical outcomes in patients with non-small cell lung cancer (NSCLC) …

Background Despite the progress in the development of next‐generation sequencing (NGS),
diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low …

The technique 3'rapid amplification of cDNA ends (3′ RACE) allows for detection of
translocations with unknown gene partners located at the 3′ end of the chimeric transcript …

The management of lung cancer (LC) requires the analysis of a diverse spectrum of
molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF …

Comprehensive molecular testing plays a critical role in the choice of treatment for non-small
lung cell cancer (NSCLC). The analysis of druggable alterations in EGFR, BRAF, MET …